His primary areas of study are Stroke, Internal medicine, Fibrinolytic agent, Cardiology and Perfusion scanning. His research integrates issues of Randomized controlled trial, Surgery and Magnetic resonance imaging in his study of Stroke. His study in Surgery is interdisciplinary in nature, drawing from both Clinical trial and Desmoteplase.
His studies deal with areas such as Emergency medical services, Emergency department, Placebo, Modified Rankin Scale and Tissue plasminogen activator as well as Fibrinolytic agent. In his research, Severity of illness and Stroke recovery is intimately related to Logistic regression, which falls under the overarching field of Cardiology. His work investigates the relationship between Perfusion scanning and topics such as Penumbra that intersect with problems in Infarction and Pathology.
Mark W. Parsons mainly focuses on Stroke, Internal medicine, Thrombolysis, Cardiology and Perfusion scanning. His Stroke research integrates issues from Radiology, Perfusion and Surgery. His work on Brain ischemia, Modified Rankin Scale, Cerebral infarction and Clinical trial as part of general Internal medicine study is frequently linked to Clinical neurology, bridging the gap between disciplines.
His Thrombolysis research incorporates themes from Randomized controlled trial, Emergency medicine, Magnetic resonance imaging, Tissue plasminogen activator and Acute stroke. His Cardiology study combines topics from a wide range of disciplines, such as Prospective cohort study and Acute ischemic stroke, Ischemic stroke. The various areas that Mark W. Parsons examines in his Perfusion scanning study include Cerebral blood flow and Receiver operating characteristic.
Stroke, Internal medicine, Thrombolysis, Cardiology and Perfusion scanning are his primary areas of study. The study incorporates disciplines such as Odds ratio, Clinical trial and Perfusion in addition to Stroke. His Thrombolysis study integrates concerns from other disciplines, such as Reperfusion therapy, Interquartile range, Medical emergency, Emergency medicine and Tissue plasminogen activator.
He usually deals with Cardiology and limits it to topics linked to Ischemic stroke and Endovascular therapy and Ischemia. His Perfusion scanning research includes themes of Fluid-attenuated inversion recovery, Wake up stroke and Angiography. His Fibrinolytic agent research is multidisciplinary, incorporating perspectives in Anesthesia and Brain ischemia.
His primary areas of investigation include Stroke, Thrombolysis, Internal medicine, Cardiology and Fibrinolytic agent. His Stroke study incorporates themes from Odds ratio, Decision support system and Perfusion. His Thrombolysis research is multidisciplinary, incorporating elements of Reperfusion therapy, Modified Rankin Scale, Randomized controlled trial and Emergency medicine.
His research in Randomized controlled trial intersects with topics in Relative risk and Placebo. His work focuses on many connections between Cardiology and other disciplines, such as Interquartile range, that overlap with his field of interest in Thrombus. Mark W. Parsons combines subjects such as Anesthesia, Brain ischemia and Tenecteplase with his study of Fibrinolytic agent.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials
Jonathan Emberson;Kennedy R Lees;Patrick Lyden;Lisa Blackwell.
The Lancet (2014)
Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage
Craig S. Anderson;Emma Heeley;Yining Huang;Jiguang Wang.
The New England Journal of Medicine (2013)
Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial.
Stephen M Davis;Geoffrey A Donnan;Mark W Parsons;Christopher Levi.
Lancet Neurology (2008)
Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial.
Craig S Anderson;Yining Huang;Ji Guang Wang;Hisatomi Arima;Hisatomi Arima.
Lancet Neurology (2008)
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
W. N. Kernan;C. M. Viscoli;K. L. Furie;L. H. Young.
The New England Journal of Medicine (2016)
Persistent Poststroke Hyperglycemia Is Independently Associated With Infarct Expansion and Worse Clinical Outcome
Tracey A. Baird;Mark W. Parsons;Thanh Phan;Ken S. Butcher.
Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study
Mark W. Parsons;P. Alan Barber;Patricia M. Desmond;Tracey A. Baird;Tracey A. Baird.
Annals of Neurology (2002)
A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.
Mark Parsons;Neil Spratt;Andrew Bivard;Bruce Campbell.
The New England Journal of Medicine (2012)
The independent predictive utility of computed tomography angiographic collateral status in acute ischaemic stroke
Ferdinand Miteff;Christopher R. Levi;Christopher R. Levi;Grant A. Bateman;Neil Spratt;Neil Spratt.
Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke
Bruce C.V. Campbell;Peter J. Mitchell;Leonid Churilov;Nawaf Yassi.
The New England Journal of Medicine (2018)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: